Goldman Sachs raised the firm’s price target on Eli Lilly (LLY) to $1,145 from $951 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly price target lowered to $1,268 from $1,286 at BofA
- Eli Lilly & Co: Strategic Initiatives and Promising Market Opportunities Drive Buy Rating
- Eli Lilly’s Mounjaro recommended for extended use by EMA
- Eli Lilly’s New Study on LY3549492: A Potential Breakthrough in Obesity Treatment
- Eli Lilly’s New Study on LY4213663: A Potential Game-Changer for Rheumatoid Arthritis?